Clinical trial
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7836748 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Participants With Advanced Solid Tumors With a RAS G12V Mutation
NCT07905924 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7836748 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Participants With Advanced Solid Tumors With a RAS G12V Mutation
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- March 30, 2032
- Enrollment
- 540 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumors
Lead sponsor's other trials
Hoffmann-La Roche, most recent start first.
+2,095 more trials See the organization page